Alexion initiated with a Neutral at Guggenheim

Guggenheim analyst Yatin Suneja initiated with a Neutral rating and $135 price target, stating that he believes much of the growth in Soliris’s approved indications is abating and the launch of next-gen Ultomiris could further taper some of the remaining growth. He also sees a lack of meaningful catalysts in the next 12 months.

https://thefly.com/landingPageNews.php?id=2868514